It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

Awareness about the risk of hearing loss after ototoxic

2 treatments in Swiss childhood cancer survivors

3 **1. Authors**

Philippa Jörger^{1,2}, Carina Nigg¹, Maša Žarković^{1,2}, Grit Sommer¹, Martin Kompis³,
Gisela Michel⁴, Marc Ansari^{5,6}, Nicolas Waespe^{1,5,7}, Claudia E. Kuehni^{1,7}⊠

6

7 **1.1 Affiliations**

- 8
- Institute of Social and Preventive Medicine, University of Bern, Bern,
 Switzerland
 Graduate School for Health Sciences, University of Bern, Bern,
- 12 Switzerland 13 3 Department of ENT Head and Neck Surgery Inselspital University
- Department of ENT, Head and Neck Surgery Inselspital, University
 Hospital Bern and University of Bern, Bern, Switzerland
- Faculty of Health Sciences and Medicine University of Lucerne, Lucerne,
 Switzerland
- 5. CANSEARCH research platform in pediatric oncology and hematology,
 Department of Pediatrics, Gynecology and Obstetrics, University of
 Geneva, Geneva, Switzerland
- Department of Women, Child and Adolescent, Division of Pediatric
 Oncology and Hematology, Geneva University Hospital, University of
 Geneva, Geneva, Switzerland
- Division of Pediatric Hematology/Oncology, Department of Pediatrics,
 Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 25 26
- 27 \bowtie Corresponding author:
- 28 Correspondence to:
- 29 Claudia E. Kuehni, Prof. MD;
- 30 Institute of Social and Preventive Medicine, University of Bern,
- 31 Mittelstrasse 43, 3012 Bern, Switzerland;
- 32 email: claudia.kuehni@unibe.ch; Telephone: +41 31 684 35 07
- 33

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

35 2. Abstract

36	Objectives: The International Guideline Harmonization Group recommends
37	childhood cancer survivors (CCS) exposed to ototoxic treatments be aware of the
38	risk of hearing loss. We assessed awareness among adult CCS.
39	Methods: We identified adults diagnosed with cancer <20 years who received
40	ototoxic treatments through the Swiss Childhood Cancer Registry (ChCR) and
41	invited them to the HEAR-study. Participants completed a questionnaire and
42	underwent pure-tone audiometry. Cancer and treatment data came from the
43	ChCR. We used logistic regression to explore factors influencing awareness.
44	Results: 105 of 424 invited CCS participated (25%). 57% did not remember
45	receiving information on hearing loss prior to the study. CCS who remembered
46	being informed were more likely diagnosed after 1995 (OR: 4.5, 95% CI: 1.3-
47	15.4), reported hearing problems (10.9, 2.6-45.1) and other late effects (4.1, 1.3-
48	13.2), and treated with platinum chemotherapy only (10.8, 2.2-53.2) versus
49	cranial radiotherapy only. 44% of participants presented clinically relevant
50	hearing loss.
51	Conclusions: Over half of CCS exposed to ototoxic treatments were unaware of
52	their risk of hearing loss.
53	Practice Implications: Educating CCS about potential late effects of ototoxic
54	treatments is important to allow early diagnosis and treatment, especially for
55	those who had cancer longer ago and those exposed to cranial radiation.
56	

56

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss 25-Sep-24	Philippa Jörger

- 57 Keywords (7): hearing problems, childhood cancer survivors, awareness, late-
- 58 effects, ototoxicity, information provision
- 59
- 60 Highlights:
- Half of CCS exposed to ototoxic treatment were unaware of the risk of
- 62 hearing loss
- CCS treated before 1995 were less aware about the risk of hearing loss
- Information provision is key to effective monitoring and early intervention

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

66 **3. Introduction**

67 Childhood cancer survivors (CCS) are at risk of hearing loss as a late effect of 68 certain treatments [1]. Forty percent of CCS treated with platinum chemotherapy, 69 around 20% of those treated with doses of cranial radiation \geq 30 gray (Gy), and 70 varying proportions of those treated with surgery involving the auditory system 71 experience hearing loss [1–6]. Cumulative incidence of hearing loss due to these 72 treatments increases up to 15 years after completing cancer treatment [7]. 73 Among CCS, undetected hearing loss can impair language development, school 74 performance, neurocognitive functions, and overall guality of life [8–11]. Regular 75 audiometric screening enables hearing loss to be detected as early as possible 76 and allows appropriate measures to be initiated. The International Guideline 77 Harmonization Group (IGHG) recommends that CCS treated with a known 78 ototoxic treatment (cisplatin with or without high-dose carboplatin (> 1500 79 mq/m²), and/or head or brain radiotherapy \geq 30 Gy) and their health-care 80 providers "should be aware of the risk of hearing loss" [1]. IGHG recommends 81 annual hearing tests until six years of age, biannual tests until twelve years, and 82 every five years thereafter [1]. 83 Informing CCS about the risk for late effects related to their cancer treatment is 84 important to facilitate follow-up care and to manage long-term health [12,13]. 85 Previous research in Switzerland suggests CCS have limited knowledge about 86 their risks for late effects [14–16]. Studies investigating information provision on 87 specific late effects, such as hearing loss, are lacking.

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss 25-Sep-24	Philippa Jörger

88	Using data from the	HEAR-study, a health se	ervice research project on the
----	---------------------	-------------------------	--------------------------------

89 hearing of CCS, we first examined whether adult CCS who had received ototoxic

- 90 treatments were aware of their risk for hearing loss, and had had their hearing
- 91 evaluated as recommended. Second, we compared CCS who were aware of
- 92 hearing loss risk with those who were not to identify CCS at increased need for
- 93 information and support. Third, we investigated whether CCS currently
- 94 experience clinically relevant hearing loss and explored the associations between
- 95 awareness, hearing evaluation after end of treatment, and current hearing loss
- 96 based on audiometric testing.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

97 **4. Methods**

98 **4.1 Study population**

Eligible CCS were identified through the Swiss Childhood Cancer Registry
(ChCR). The ChCR is a national registry that includes all Swiss residents
diagnosed with leukemias, lymphomas, central nervous system (CNS) tumors,

102 malignant solid tumors, or Langerhans cell histiocytosis before 20 years of age

103 since 1976 [17,18]. We included CCS registered in the ChCR who had survived

104 at least two years since diagnosis, had received ototoxic treatment as defined

105 per IGHG guidelines, and were ≥ 18 years at the time of study. We excluded

106 CCS who lacked a valid address, were living outside Switzerland, did not speak

107 German or French, and had been contacted for another study in the past six

108 months (January 2022-July 2022). The Ethics Committee of the Canton of Bern

109 approved the ChCR (166/2014) and the HEAR-study (2021-01624).

110

111 **4.2 Procedures and study design**

112 The HEAR-study is a health service research project set up in 2021 at the

113 University of Bern, Switzerland. Details have been published previously [19].

114 Eligible CCS were invited by postal mail; we sent up to three reminders to CCS

115 who did not respond. CCS who responded with informed consent received an e-

116 mail request to complete an online questionnaire (Supplementary Table S6) and

117 an invitation to attend a free hearing test. Participants performed hearing tests at

118 a local hearing aid shop where a certified acoustician performed bilateral pure-

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss 25-Sep-24	Philippa Jörger

- tone audiometry (125-8000Hz) with an additional bone conduction measurement
- 120 (250-4000Hz) if the hearing threshold was > 25dB. We collected questionnaires
- 121 and audiograms between July 15, 2022, and July 15, 2023.

122

- 123 4.3 Hearing-related information
- 124 *4.3.1* Awareness about the risk of hearing loss and information on prior
- 125 hearing evaluations

126 We assessed awareness about the risk of hearing loss using a questionnaire.

127 We asked participants if they had been informed about an increased risk of

128 hearing loss (yes/no/don't know). We also asked if they had been counseled to

129 monitor their hearing after end of treatment (yes/no/don't know). If participants

130 answered yes to either of the two questions, we coded being informed as "yes".

131 Further, we asked if their hearing had ever been evaluated after end of treatment

- 132 (yes/no/don't know).
- 4.3.2 Self-reported hearing loss, perceived hearing difficulties, and other late
 effects

We asked participants if they experienced any late effects of cancer or its therapy (yes/no), and to list them. We created a variable "late effects other than hearing loss" (yes/no) for which "no" indicated participants who only listed hearing loss or nothing. If participants listed hearing loss as a late effect in the open question, the variable on self-reported hearing loss was coded as "yes". Further, we asked if they had problems following a conversation when there was background noise

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	

141 (hearing difficulties in noisy environments) (yes/no) and if they felt they did not

142 hear well (feeling of poor hearing) (yes, often/yes, sometimes/no).

143 4.3.3 Hearing loss from audiogram measurements

144 The hearing aid shops sent us audiogram results in a coded file. For grading we

145 visualized the audiograms using the R package "audiometry" (Lehnbert B, R

146 package version 0.3.0, 2021) in RStudio (R Core Team, Vienna, AUT, 2022).

147 Two trained researchers (PJ and CN) independently graded audiograms for each

148 ear according to the SIOP Boston Ototoxicity Scale [20], an established grading

149 scheme used for CCS exposed to ototoxic treatments [21,22]. We resolved

150 discrepancies through discussions with an experienced audiologist (MK). We

151 considered bone conduction measurements when there was consistently a

152 significant difference between air and bone conduction measurements (≥ 10 dB),

153 indicating a potential conductive hearing loss [20]. We used the grading of the

154 more affected ear. Severity was graded as (a) none (grade 0), (b) mild (grade 1),

155 (c) moderate (grade 2), or (d) severe hearing loss (≥ grade 3) [20]. Clinically

156 relevant hearing loss was defined as SIOP Boston grade \geq 2 [20,22].

157

158 **4.4 Participant characteristics**

159 4.4.1 Clinical and cancer-treatment related characteristics

160 The ChCR provided data on biological sex, year of birth, cancer diagnosis, age at

161 diagnosis, year of diagnosis, and type of therapy including carboplatin

162 chemotherapy, cisplatin chemotherapy, and cranial radiation.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

163

....

164 4.4.2 Information on follow-up care

165 We asked participants in the questionnaire if they were still undergoing clinical

166 follow-up care related to their cancer (yes/no), and if they had received any

167 information regarding follow-up care in general (yes/no/don't know).

168

169 4.4.3 Socioeconomic characteristics

170 The questionnaire assessed sociodemographic characteristics including

171 migration background (yes/no), participants' and their parents' education levels,

and language region (German/French). Participants were categorized as having

a migration background if at least one parent was born outside Switzerland. We

174 defined three education level categories: primary schooling (compulsory

schooling only, \leq 9 years), secondary education (vocational training, upper

176 secondary education), and tertiary education (university, or technical college).

177

178 **4.5 Statistical analysis**

First, we assessed how many CCS were aware of a risk of hearing problems (information status) and how many had completed a hearing evaluation after the end of treatment. For further analysis, we combined the categories "no" and "don't know" interpreting both as insufficient awareness. Next, we assessed severity of hearing loss and prevalence of clinically relevant hearing loss (SIOP Boston Grade \geq 2). Using univariable logistic regression, we investigated factors

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss 25-Sep-24	Philippa Jörger

185	associated with information status and having completed a hearing evaluation
186	after end of treatment (Supplementary Tables S4 and S5). We included sex, age
187	at study, time since diagnosis, age at diagnosis, year of diagnosis, language
188	region, participant and parental education, migration background, presence of
189	late effects other than hearing loss, self-reported hearing loss, general
190	information received on follow-up care, attending regular follow-up care visits,
191	and treatment (only platinum/only cranial radiation ≥ 30 Gy/both platinum and
192	cranial radiation) as explanatory variables. We categorized year of diagnosis into
193	the periods before and after 1995, reflecting a cut-off after which a decline in
194	hearing loss was observed in previous studies of CCS from Switzerland [7].
195	Information status was included as an additional explanatory variable for the
196	outcome hearing evaluation. In a multivariable logistic regression, we included all
197	exposures associated with the outcome at a significance level of $p \le 0.1$. If there
198	were missing values in independent or dependent variables, we performed
199	complete case analyses.
200	

It is made available under a CC-BY 4.0 International license .
Manuscript – Awareness Hearing loss
25-Sep-24

Philippa Jörger

202 **5. Results**

203 **5.1 Study population**

- 204 Of 573 eligible CCS exposed to ototoxic treatments, identified through the ChCR,
- 424 were invited to the study. One-hundred and five (25%) consented and
- 206 completed the questionnaire and 83 (20%) also completed a hearing test as part
- of our study (Supplementary Figure SF1). About half (n=57, 54%) of participants
- 208 were female, median age at study start was 32 years (interquartile range [IQR]:
- 209 24-37), age at diagnosis 8 years (IQR: 4-13), and median time since diagnosis
- 210 23 years (IQR: 19-32) (Table 1). Common diagnoses were malignant bone
- tumors (n=24, 23%), CNS tumors (n=23, 22%) and soft tissue sarcomas (n=22,
- 212 21%). Eighty CCS (76%) had been treated with platinum chemotherapy, and 41
- 213 (39%) with cranial radiation (Supplementary Table S2). Compared to
- 214 nonparticipants, CCS completing the questionnaire were more often female,
- 215 older at time of study, and further away from diagnosis (Supplementary Table

216 S1).

217

218

219

- 220
- 221
- 222

223

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

225 **TABLE 1** Characteristics of participants completing the questionnaire (N=105).

	Completed questionnaire N=105
Sout	n (%)
Sex	FZ (FA)
Female	57 (54)
Male	48 (46)
Age at study, years (Median, IQR)	32 (24-37)
Year of diagnosis (Median, range)	1998 (1977-2018)
1977-1995	41 (39)
1996-2005	46 (44)
2006-2018	18 (17)
Time since diagnosis, years (Median, IQR)	23 (19-32)
Age at cancer diagnosis, years (Median, IQR)	8 (4-13)
Diagnostic group of primary neoplasm (ICCC-3)	
Leukemias	0 (0)
Lymphomas	7 (7)
CNS tumors	23 (22)
Neuroblastoma	13 (12)
Retinoblastoma	3 (3)
Renal tumors	2 (2)
Hepatic tumors	$\frac{-}{4}(\frac{-}{4})$
Malignant bone tumors	24 (23)
Soft tissue sarcomas	22 (21)
Germ cell tumors	7 (7)
Other	0 (0)
Platinum Chemotherapy	- (-)
No platinum chemotherapy	23 (22)
Cisplatin	42 (40)
Carboplatin	17 (16)
Cisplatin & Carboplatin	21 (20)
Unknown	2 (2)
Cranial radiation	. /
No cranial radiation	64 (61)
<30 Gray	0 (0)
≥30 Gray	41 (39)
Unknown	0 (0)
Education	
Primary schooling	5 (5)
Secondary education	57 (54)
Tertiary education	43 (41)

226

- 227 Abbreviations: IQR, Interquartile range. n, number. ICCC-3, international classification of
- 228 childhood cancer, edition 3

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

230 **5.2 Information status and prior hearing evaluation**

- Among 105 participants, 46 (44%, 95% confidence interval [CI]: 35-54%)
- 232 reported having received information or advice regarding risk of hearing loss or
- 233 necessity of conducting hearing tests after end of treatment, while 31 (30%, 95%
- CI: 22-39%) reported not having received information/advice and 28 (27%, 95%)
- 235 CI: 19-36%) did not remember (Figure 1). Similarly, 40 (38%, 95% CI: 29-48%)
- 236 participants reported having completed a hearing evaluation after end of
- treatment, 34 (32%, 95% CI: 24-42%) reported not having completed a hearing
- 238 evaluation, and 31 (30%, 95% CI: 22-39%) did not remember. Of the 40
- participants reporting a hearing evaluation, 13 (33%) had done it in the last 5
- years, 12 (30%) longer ago, and 15 (38%) did not remember the year of their last
- 241 hearing evaluation (Supplementary Table S3).
- 242 We visualized the relationship between information status and prior hearing
- evaluation using a proportional Venn diagram (Figure 1). Most CCS who were
- informed also had their hearing evaluated at some point after treatment.

245

5.3 Degree of hearing loss and information status, self-reported hearing
 loss, and prior hearing evaluation

248 Of 83 participants who completed a hearing test for the study, 29 had normal

- 249 hearing (35%, 95% CI: 25-46), 17 (20%, 95% CI: 13-31%) had mild, 11 (13%,
- 250 95% CI: 7-23%) moderate, and 26 (31%, 95% CI: 22-42%) severe hearing loss,
- resulting in 37 participants (45%, 95% CI: 34-56%) with clinically relevant hearing
- loss. Among the 36 participants with clinically relevant hearing loss who

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	

	· · ·
253	completed the questionnaire, 20 (56%, 95% CI: 39-71%) reported having
254	received information/advice regarding their risk for hearing loss and 14 (39%,
255	95% CI: 24-56%) reported having had their hearing evaluated after end of
256	treatment. Further, 19 (53%, 95% CI: 36-69%) of the participants with clinically
257	relevant hearing loss reported prior hearing problems in the questionnaire, 29
258	(81%, 95% CI: 64-91%) reported hearing difficulties in noisy environments, and
259	30 (83%, 95% CI: 67-93%) sometimes or often felt like they were not hearing
260	well. (Figure 2)
261	
262	5.4 Factors associated with information status and hearing evaluation
263	after end of treatment
264	Participants informed about risk of hearing loss were diagnosed more often after
265	1995 (odds ratio [OR]: 4.5, 95% CI: 1.3-15.4), reported more prior hearing
266	problems (OR: 10.9, 95% CI: 2.6-45.1) and other late effects (OR: 4.1, 95% CI:
267	1.3-13.2), and were more often treated with platinum chemotherapy (OR: 10.8,
268	95% CI: 2.2-53.2) or both platinum chemotherapy and cranial radiotherapy (OR:
269	6.5, 95% CI: 1.0-41.8) compared to cranial radiotherapy alone (Table 2). Those
270	who were informed were more likely to have had their hearing evaluated after
271	end of treatment (OR: 13.6, 95% CI: 3.8-48.3).
272	
273	
274	

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	

276

- 277 **TABLE 2** Factors associated with a) having received information/advice about
- 278 hearing loss, and b) having ever completed a hearing evaluation after therapy;

279 results from multivariable regressions.

Multivariable (95%-CI)	Informed/Advised ^{a,b}	Hearing evaluated ^{a,b}
	N=102	N=102
	OR (95%-CI)	OR (95%-CI)
Period of cancer diagnosis	· · · ·	· · · · · · · · · · · · · · · · · · ·
≤1995	1.0	1.0
>1995	4.5 (1.3-15.4)	2.2 (0.6-8.5)
Late effects other than hearing loss	· · · · ·	· · · ·
No	1.0	1.0
Yes	4.1 (1.3-13.2)	2.8 (0.8-9.6)
Self-reported hearing loss		· · · · ·
No	1.0	1.0
Yes	10.9 (2.6-45.1)	0.7 (0.2-2.7)
Maternal education		
Primary or secondary education	1.0	1.0
Tertiary education	1.7 (0.5-5.5)	1.6 (0.5-5.3)
General information received on follow-up care		· · · ·
No	1.0	1.0
Yes	1.1 (0.4-3.3)	1.3 (0.4-4.4)
Information/advice received on hearing loss and		
hearing screening		
No	‡ ±	1.0
Yes	‡	13.6 (3.8-48.3)
Regular visit of follow-up care		
No	1.0	1.0
Yes	1.9 (0.6-6.6)	1.0 (0.2-3.8)
Treatment group		
Cranial radiation ≥30 Gray only	1.0	1.0
Platinum Chemotherapy only	10.8 (2.2-53.2)	1.8 (0.3-9.4)
Both	6.5 (1.0-41.8)	0.9 (0.1-6.4)

280

The respective multivariable model was adjusted for variables with a p-value of 0.1 or less in the univariable logistic regression.

^a, People with missing maternal education and missing treatment group were excluded from the logistic regression (n=3).

285 ^b, Age at study start and years since diagnosis were omitted from multivariable 286 regression for collinearity with year of diagnosis.

287 ‡, Exposure equal to outcome

288 Abbreviations: CI, Confidence Interval. OR, Odds Ratio. n, number.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

290 6. Discussion and Conclusion

291 **6.1 Summary of findings**

292 This study found that over half of CCS who received ototoxic treatment reported 293 they were unaware of the risk of hearing loss even though international 294 guidelines recommend that they be aware. More than half did not remember 295 having ever had their hearing evaluated after end of treatment. We found a 296 strong association between being informed and having had a hearing evaluation. 297 Almost half of participants had clinically relevant hearing loss assessed by pure-298 tone audiometry, yet almost half of those did not report hearing problems in the 299 questionnaire, which suggests they were not aware of their hearing loss.

300

301 6.2 Information status

302 Previous surveys on information provision and information needs among Swiss 303 CCS show that approximately one-third of survivors do not remember having ever received general information about potential late effects of their cancer or 304 305 therapy, and about 80% of CCS wish to be better informed [14–16]. In this study, 306 56% of CCS did not remember receiving information about the risk for hearing 307 loss. This is comparable to a Norwegian study about information provision in 308 which up to 60% of cancer survivors overall did not recall receiving information 309 on late effects including hearing loss, though the study also included survivors 310 without ototoxic treatments [12]. A study from Hong Kong assessing knowledge 311 about risk-based, exposure-related late effects found that, similar to our study,

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss Philippa Jörger 25-Sep-24

almost 60% of CCS were not aware of potential hearing problems following

313 ototoxic treatments [13].

314

315 6.2.1 Associations with information status

316 Consistent with other studies [12,14,15], we found that CCS seem to be less well

317 informed the more time has passed since diagnosis. A reason for this might be

318 that parents of patients who were younger children were the primary recipients of

319 information [23]. Parents might not have passed on the information to their

320 children, or CCS may have forgotten it given a long median time of 22 years

321 since diagnosis.

322 We found that CCS diagnosed after 1995 were better informed, which is likely

323 due to advances in knowledge about long-term effects of ototoxic treatments. For

324 example, the American Speech-Language-Hearing Association (ASHA) guideline

325 from 1994 recommended monitoring the hearing at least until one year post-

326 treatment with platinum agents and only longer if hearing loss was detected [24].

327 Considering that one-third of our study population was diagnosed before 1995,

328 they likely received outdated or limited information about potential long-term

329 effects.

330 The 1994 ASHA guideline further stated that cranial radiation alone has little

effect on hearing [24], and many clinicians might be less aware of the effect of

cranial radiation on hearing than platinum chemotherapy. This might explain why

333 participants who received cranial radiation \geq 30 Gy alone were less informed

than participants treated with platinum agents. This aligns with a previous record-

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	

335	based study in which we found that CCS treated with cranial radiation \ge 30 Gy
336	were less likely to have received post-therapy hearing evaluations than CCS
337	treated with platinum chemotherapy [25]. Participants reporting other late effects
338	were more informed about the risk of hearing loss, suggesting that CCS with
339	multiple late effects are generally more aware of treatment-related complications
340	[26].

341

342 **6.3 Hearing evaluations after end of treatment**

343 A retrospective, record-based study examining audiological evaluations post-344 therapy in Switzerland found that 28% of CCS at risk for hearing loss had not had 345 any hearing evaluations after end of treatment [25]. This is comparable to the 346 32% observed in our study. In our study, a further 30% did not recall undergoing 347 any hearing evaluations. While they might have had an initial test, CCS may not 348 have had subsequent assessments when their hearing test result was normal as 349 specified in older ASHA and Children's Oncology Group Long-Term Follow-Up 350 Guidelines [24,27]. Given that initial hearing tests often occur during or soon after 351 treatment, many may have forgotten about them or were not contacted for later 352 hearing evaluations as currently recommended [1].

353

354 **6.4 Degree of hearing loss and self-reported hearing loss**

355 We previously reported that 36% of CCS had clinically relevant hearing loss after 356 platinum-based therapy according to the SIOP Boston ototoxicity scale [28]. This

.. . .

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	

357	new study finds a higher prevalence (47%) of clinically relevant hearing loss,
358	likely because of different characteristics of the study population, which now is
359	older and further from diagnosis and more recently represents the survivor
360	cohort. Considering the newer study's low response rate, selection bias could
361	have also played a role in the difference.
362	Almost half of our study participants with clinically relevant hearing loss did not
363	report hearing problems as late effects in the questionnaire, suggesting they
364	were not aware of them. The proportion of participants with hearing problems by
365	SIOP Boston grade who did not self-report hearing loss was higher than that
366	found in a previous study in which we compared questionnaire-reported hearing
367	loss with audiometry results [29]. In that study, only 14% of CCS who did not self-
368	report hearing loss had hearing loss in the SIOP-Boston grade range from 1 to 4.
369	In the current study, self-reported hearing loss was assessed using an open
370	question about known late effects. We have potentially underestimated the
371	proportion of participants who are aware about their hearing loss since some
372	participants with hearing loss may not have listed it as a late effect.

373

6.5 Strengths and limitations

A strength of this study is the population-based sample with comprehensive cancer-related medical data provided by the Swiss ChCR. Combined with the questionnaire-based information and recent audiograms, our dataset allowed for a thorough analysis. Study limitations include the response rate of 25% which, as noted above, potentially introduced a selection bias. However, although analyses revealed some statistically significant differences between responders and

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss 25-Sep-24	Philippa Jörger

nonresponders regarding cancer-related characteristics, differences were modest
based upon effect sizes. The low response rate may be due to the study settings
as CCS had not only to return a questionnaire but also visit a hearing aid shop
for a hearing test.

384

385 6.6 Conclusion

386 A large proportion of CCS are not aware of the potential risk of hearing loss due

to their treatment. Among those who are aware of this late effect, most have

388 undergone hearing evaluations. From this we conclude that knowledge is key to

timely interventions that can mitigate the effects of hearing loss. Caregivers,

390 parents, and CCS should always have the latest information on late effects and

follow-up care at hand to manage and protect auditory health throughout the lives

392 of CCS—even those with decades intervening since treatment.

393

394 **6.7 Practice implications**

How do we best manage survivorship to follow up treatment and address

396 potential late effects? In addition to direct, clinical support of CCS and parents,

397 electronic patient records continue to evolve and will improve the retention and

398 support the acquisition of knowledge accessible by both providers and patients.

399 A specific proposal for enhancing information access and retention for CCS is the

400 Survivorship Passport, or SurPass [30]. This tool can provide crucial details

401 about a survivor's medical history and a tailored plan for follow-up to caregivers,

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss 25-Sep-24	Philippa Jörger

402	and information for CCS that can inform their own decision-making; a	ccessible
-----	--	-----------

403 online, it can be continually updated by new research findings. Highly secure yet

- 404 accessible electronic records such as the SurPass can sustain awareness
- 405 among caregivers and CCS wherever their journey through survivorship takes
- 406 them.

407

408 **7. Abbreviations**

- 409 ASHA American Speech-Language-Hearing Association
- 410 CCS Childhood cancer survivor
- 411 COG Children's Oncology Group
- 412 CI Confidence interval
- 413 IQR Interquartile range
- 414 Gy Gray

415

416 8. Acknowledgements

We thank the study team of the Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, the Swiss Childhood Cancer Survivor Study, and the team of the Swiss Childhood Cancer Registry. We thank Christopher Ritter from the editorial service of the Institute of Social and Preventive Medicine at the University of Bern for the editorial suggestions. We thank all childhood cancer survivors participating in the study.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

424 **9. CRediT authorship contribution statement**

425 Philippa Jörger: formal analysis, investigation, writing—original draft, review & 426 editing, visualization, project administration. Carina Nigg: formal analysis, 427 writing—original draft, review & editing, supervision. Maša Žarković: formal 428 analysis, writing—original draft, review & editing. Grit Sommer: writing—review 429 & editing. Martin Kompis: formal analysis, writing—review & editing, funding 430 acquisition. Gisela Michel: writing—review & editing, funding acquisition. Marc 431 Ansari: conceptualization, writing-review & editing, supervision, funding 432 acquisition. **Nicolas Waespe:** writing—review & editing, funding acquisition. 433 Claudia Kuehni: conceptualization, methodology, formal analysis, writing-434 review & editing, supervision, project administration, funding acquisition.

435

436 **10.** Funding sources

This work was financially supported by the Swiss Cancer League and Swiss
Cancer Research (grant number HSR-4951-11-2019, KLS/KFS-5711-01-2022,
and KFS-5302-02-2021). The CANSEARCH foundation, Kinderkrebs Schweiz
Foundation, and Zoé4Life Foundation supported NW.

441 **11. Declaration of competing interest**

Nicolas Waespe reports a relationship with Swedish Orphan Biovitrum AB that
includes advisory board membership, consulting, and travel reimbursement and
a relationship with Novartis that includes advisory board membership. None of
these relationships are in association with the current study.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss Philippa Jörger 25-Sep-24

446 **12. References**

447	[1]	E. Clemens, M.M. van den Heuvel-Eibrink, R.L. Mulder, L.C.M. Kremer,
448		M.M. Hudson, R. Skinner, L.S. Constine, J.K. Bass, C.E. Kuehni, T.
449		Langer, E.C. van Dalen, E. Bardi, NX. Bonne, P.R. Brock, B. Brooks, B.
450		Carleton, E. Caron, K.W. Chang, K. Johnston, K. Knight, P.C. Nathan, E.
451		Orgel, P.K. Prasad, J. Rottenberg, K. Scheinemann, A.C.H. de Vries, T.
452		Walwyn, A. Weiss, A. Am Zehnhoff-Dinnesen, R.J. Cohn, W. Landier,
453		International Guideline Harmonization Group ototoxicity group,
454		Recommendations for ototoxicity surveillance for childhood, adolescent,
455		and young adult cancer survivors: a report from the International Late
456		Effects of Childhood Cancer Guideline Harmonization Group in
457		collaboration with the PanCare Consortium., Lancet Oncol 20 (2019) e29-
458		e41. https://doi.org/10.1016/S1470-2045(18)30858-1.

L.K. Dillard, L. Lopez-Perez, R.X. Martinez, A.M. Fullerton, S. Chadha,
C.M. McMahon, Global burden of ototoxic hearing loss associated with
platinum-based cancer treatment: A systematic review and meta-analysis.,

 462
 Cancer
 Epidemiol
 79
 (2022)
 102203.

 463
 https://doi.org/10.1016/j.canep.2022.102203.
 102203.
 102203.

464 [3] B. Murphy, A. Jackson, J.K. Bass, D.S. Tsang, C.M. Ronckers, L. Kremer,
465 S. Baliga, A. Olch, A.H. Zureick, K.-W. Jee, L.S. Constine, T.I. Yock,
466 Modeling the Risk of Hearing Loss From Radiation Therapy in Childhood
467 Cancer Survivors: A PENTEC Comprehensive Review., Int J Radiat Oncol
468 Biol Phys 119 (2024) 446–456. https://doi.org/10.1016/j.ijrobp.2023.08.016.

It is made available under a CC-BY 4.0 International license .	
Manuscript – Awareness Hearing loss 25-Sep-24	Philippa Jörger

469 [4]	4]	D.L. Kwong, W.I. Wei, J.S. Sham, W.K. Ho, P.W. Yuen, D.T. Chua, D.K.
470		Au, P.M. Wu, D.T. Choy, Sensorineural hearing loss in patients treated for
471		nasopharyngeal carcinoma: a prospective study of the effect of radiation
472		and cisplatin treatment., Int J Radiat Oncol Biol Phys 36 (1996) 281-9.
473		https://doi.org/10.1016/s0360-3016(96)00302-1.

- J.K. Bass, C.-H. Hua, J. Huang, A. Onar-Thomas, K.K. Ness, S. Jones, S.
 White, S.P. Bhagat, K.W. Chang, T.E. Merchant, Hearing Loss in Patients
 Who Received Cranial Radiation Therapy for Childhood Cancer., J Clin
 Oncol 34 (2016) 1248–55. https://doi.org/10.1200/JCO.2015.63.6738.
- 478 G.B. Williams, L.E. Kun, J.W. Thompson, H.J. Gould, R.M.S. Stocks, [6] 479 Hearing loss as a late complication of radiotherapy in children with brain 480 tumors., Ann Otol Rhinol Laryngol 114 (2005)328-31. 481 https://doi.org/10.1177/000348940511400413.
- 482 [7] A. Weiss, G. Sommer, R. Kasteler, K. Scheinemann, M. Grotzer, M.
 483 Kompis, C.E. Kuehni, Swiss Pediatric Oncology Group (SPOG), Long-term
 484 auditory complications after childhood cancer: A report from the Swiss
 485 Childhood Cancer Survivor Study., Pediatr Blood Cancer 64 (2017) 364–
 486 373. https://doi.org/10.1002/pbc.26212.
- J.K. Bass, W. Liu, P. Banerjee, T.M. Brinkman, D.A. Mulrooney, A. Gajjar,
 A.S. Pappo, T.E. Merchant, G.T. Armstrong, D. Srivastava, L.L. Robison,
 M.M. Hudson, K.R. Krull, Association of Hearing Impairment With
 Neurocognition in Survivors of Childhood Cancer., JAMA Oncol 6 (2020)
 1363–1371. https://doi.org/10.1001/jamaoncol.2020.2822.

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	

492 [9]	A. Weiss, G. Sommer, C. Schindera, L. Wengenroth, A. Karow, M. Diezi,
493	G. Michel, C.E. Kuehni, Swiss Paediatric Oncology Group (SPOG),
494	Hearing loss and quality of life in survivors of paediatric CNS tumours and
495	other cancers., Qual Life Res 28 (2019) 515–521.
496	https://doi.org/10.1007/s11136-018-2021-2.

497 M. Khairi Md Daud, R.M. Noor, N.A. Rahman, D.S. Sidek, A. Mohamad, [10] 498 The effect of mild hearing loss on academic performance in primary school 499 children., Int J Pediatr Otorhinolaryngol 74 (2010)67–70. 500 https://doi.org/10.1016/j.jporl.2009.10.013.

- 501 S. Strebel, K. Baust, D. Grabow, J. Byrne, T. Langer, A. Am Zehnhoff-[11] 502 Dinnesen, R. Kuonen, A. Weiss, T. Kepak, J. Kruseova, C. Berger, G. 503 Calaminus, G. Sommer, C.E. Kuehni, PanCareLIFE Consortium, Auditory 504 complications among childhood cancer survivors and health-related quality 505 life: PanCareLIFE study., J Cancer Surviv (2023) 1-12. of а 506 https://doi.org/10.1007/s11764-023-01456-4.
- 507 [12] M.E. Gianinazzi, C.E. Kiserud, E. Ruud, H.C. Lie, Who Knows? Information 508 Received, and Knowledge about, Cancer, Treatment and Late Effects in a 509 National Cohort of Long-Term Childhood, Adolescent and Young Adult 510 Cancer Survivors., Cancers (Basel) 14 (2022)1534. 511 https://doi.org/10.3390/cancers14061534.

512 [13] C.-T. Ma, H.W. Chou, T.T.-N. Lam, Y.T. Tung, Y.W. Lai, L.-K. Lee, V.W.-Y.
513 Lee, N.C.-Y. Yeung, A.W.-K. Leung, S. Bhatia, C.K. Li, Y.T. Cheung,
514 Provision of a personalized survivorship care plan and its impact on

It is made available under a CC-BY 4.0 International license.

Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	

515	cancer-rela	ated health	literacy am	ong childho	od canc	er survivors	in Hong
516	Kong.,	Pediatr	Blood				
517	https://doi.	org/10.1002/	/pbc.30084				

518 [14] M.E. Gianinazzi, S. Essig, C.S. Rueegg, N.X. von der Weid, P. Brazzola,

519 C.E. Kuehni, G. Michel, Swiss Paediatric Oncology Group (SPOG),
520 Information provision and information needs in adult survivors of childhood

- 521 cancer., Pediatr Blood Cancer 61 (2014) 312–8. 522 https://doi.org/10.1002/pbc.24762.
- 523 [15] S. Christen, E. Weishaupt, J. Vetsch, C.S. Rueegg, L. Mader, S. Dehler, G.
 524 Michel, Perceived information provision and information needs in
 525 adolescent and young adult cancer survivors., Eur J Cancer Care (Engl) 28
 526 (2019) e12892. https://doi.org/10.1111/ecc.12892.
- 527 [16] Y. Sievers, K. Roser, K. Scheinemann, G. Michel, A. Ilic, The information
 528 needs of relatives of childhood cancer patients and survivors: A systematic
 529 review of quantitative evidence., Patient Educ Couns 126 (2024) 108316.
 530 https://doi.org/10.1016/j.pec.2024.108316.
- 531 [17] Childhood Cancer Registry, Childhood Cancer Registry (ChCR), (2023).
 532 https://www.childhoodcancerregistry.ch/ (accessed August 1, 2023).
- 533 [18] G. Michel, N.X. von der Weid, M. Zwahlen, M. Adam, C.E. Rebholz, C.E.
 534 Kuehni, Swiss Childhood Cancer Registry, Swiss Paediatric Oncology
 535 Group (SPOG) Scientific Committee, The Swiss Childhood Cancer
 536 Registry: rationale, organisation and results for the years 2001-2005.,

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	

137

(2007)

502-9.

538 https://doi.org/10.4414/smw.2007.11875.

Med

Swiss

537

539 [19] P. Jörger, C. Nigg, L. Mader, S. Strebel, M. Kompis, Z. Tomášiková, C.
540 Schindera, G. Michel, N.X. Von Der Weid, M. Ansari, N. Waespe, C.E.
541 Kuehni, Protocol for a low-threshold screening program to detect hearing
542 loss in childhood cancer survivors in Switzerland: The HEAR-study, JMIR
543 Preprints (2024). https://doi.org/10.2196/preprints.63627.

Wkly

544 [20] P.R. Brock, K.R. Knight, D.R. Freyer, K.C.M. Campbell, P.S. Steyger, B.W.
545 Blakley, S.R. Rassekh, K.W. Chang, B.J. Fligor, K. Rajput, M. Sullivan,
546 E.A. Neuwelt, Platinum-induced ototoxicity in children: a consensus review
547 on mechanisms, predisposition, and protection, including a new
548 International Society of Pediatric Oncology Boston ototoxicity scale., J Clin
549 Oncol 30 (2012) 2408–17. https://doi.org/10.1200/JCO.2011.39.1110.

550 [21] A. Khan, A. Budnick, D. Barnea, D.R. Feldman, K.C. Oeffinger, E.S.
551 Tonorezos, Hearing Loss in Adult Survivors of Childhood Cancer Treated
552 with Radiotherapy., Children (Basel) 5 (2018) 59.
553 https://doi.org/10.3390/children5050059.

554 [22] D.J. Moke, C. Luo, J. Millstein, K.R. Knight, S.R. Rassekh, B. Brooks,
555 C.J.D. Ross, M. Wright, V. Mena, T. Rushing, A.J. Esbenshade, B.C.
556 Carleton, E. Orgel, Prevalence and risk factors for cisplatin-induced
557 hearing loss in children, adolescents, and young adults: a multi-institutional
558 North American cohort study., Lancet Child Adolesc Health 5 (2021) 274–
559 283. https://doi.org/10.1016/S2352-4642(21)00020-1.

It is made available under a CC-BY 4.0 International license .	
Manuscript – Awareness Hearing loss 25-Sep-24	Philippa Jörger

560	[23]	S. Palmer, A. Mitchell, K. Thompson, M. Sexton, Unmet needs among
561		adolescent cancer patients: a pilot study., Palliat Support Care 5 (2007)
562		127–34. https://doi.org/10.1017/s1478951507070198.

- 563 [24] American Speech-Language-Hearing Association, Audiologic Management
 564 of Individuals Receiving Cochleotoxic Drug Therapy, (1994).
 565 https://doi.org/10.1044/policy.GL1994-00003.
- 566 [25] A. Weiss, R. Kuonen, H. Brockmeier, M. Grotzer, C. Candreia, R. Maire, P.
- 567 Senn, C. Stieger, J. Rosenfeld, D. Veraguth, M. Kompis, K. Scheinemann,
- 568 C.E. Kuehni, Swiss Pediatric Oncology Group (SPOG), Audiological 569 monitoring in Swiss childhood cancer patients., Pediatr Blood Cancer 65 570 (2018) e26877. https://doi.org/10.1002/pbc.26877.
- 571 [26] C. Signorelli, C.E. Wakefield, J.E. Fardell, W.H.B. Wallace, E.G.
 572 Robertson, J.K. McLoone, R.J. Cohn, The impact of long-term follow-up
 573 care for childhood cancer survivors: A systematic review., Crit Rev Oncol
 574 Hematol
 114 (2017)
 131–138.
- 575 https://doi.org/10.1016/j.critrevonc.2017.04.007.
- 576 [27] Children's Oncology Group, Long-Term Follow-Up Guidelines for Survivors
 577 of Childhood, Adolescent, and Young Adult Cancers Version 4.0, (2013).
 578 www.survivorshipguidelines.org (accessed February 15, 2024).
- 579 [28] S. Strebel, L. Mader, T. Sláma, N. Waespe, A. Weiss, R. Parfitt, A. Am
 580 Zehnhoff-Dinnesen, M. Kompis, N.X. von der Weid, M. Ansari, C.E.
 581 Kuehni, Severity of hearing loss after platinum chemotherapy in childhood

	It is made available under a CC-BY 4.0 International license .	
25-Sen-24	Manuscript – Awareness Hearing loss	Philippa Jörger
	25-Sep-24	

582	cancer	survivors.,	Pediatr	Blood	Cancer	69	(2022)	e29755.
583	https://doi.org/10.1002/pbc.29755.							

- 584 [29] A. Weiss, G. Sommer, R. Kuonen, K. Scheinemann, M. Grotzer, M.
 585 Kompis, C.E. Kuehni, Swiss Paediatric Oncology Group (SPOG),
 586 Validation of questionnaire-reported hearing with medical records: A report
 587 from the Swiss Childhood Cancer Survivor Study., PLoS One 12 (2017)
- 588 e0174479. https://doi.org/10.1371/journal.pone.0174479.
- 589 [30] R. Haupt, S. Essiaf, C. Dellacasa, C.M. Ronckers, S. Caruso, E. Sugden,
- 590 L. Zadravec Zaletel, M. Muraca, V. Morsellino, A. Kienesberger, A.
- 591 Blondeel, D. Saraceno, M. Ortali, L.C.M. Kremer, R. Skinner, J. Roganovic,
- 592 F. Bagnasco, G.A. Levitt, M. De Rosa, M. Schrappe, L. Hjorth, R.
- 593 Ladenstein, PanCareSurFup, ENCCA Working Group, ExPo-r-Net Working
- 594 Group, The "Survivorship Passport" for childhood cancer survivors., Eur J
- 595 Cancer 102 (2018) 69–81. https://doi.org/10.1016/j.ejca.2018.07.006.

597




FIGURE 1 Participant responses to questions on awareness and prior hearing evaluation. 598

599

600 Participants who reported (a) having been informed or advised about the possibility of hearing loss and the need for hearing tests after completing 601 therapy and (b) having had a hearing evaluation after completing the therapy. Proportional Venn-Diagram depicting the relation between having 602 been informed or advised and having had a hearing evaluation.

603 Numbers represent the number (n) and percentage (%) of participants reporting yes to the respective question; (a) Informed/Advised, Were you 604 informed about hearing loss as a potential late effect of your treatment / Have you been advised to have your hearing checked after completing 605 your therapies? (b) Hearing evaluated, Has your hearing ever been checked after you finished your treatment? No/Don't know; Answered no or do606 not know to both questions.

607 Abbreviations:

n,

number.

It is made available under a CC-BY 4.0 International license

It is made available under a CC-BY 4.0 International license .	
Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	


608 **FIGURE 2** Degree of hearing loss assessed with audiograms and

.. . .

609 graded according to SIOP Boston ototoxicity scale, and responses of

610 questions on awareness with clinically relevant hearing loss (Grade

611 ≥2).



612

613 (left) Degree of hearing loss according to SIOP Boston Ototoxicity Scale for participants with 614 available audiograms, N=83. No hearing loss, grade 0. Mild, grade 1. Moderate, grade 2. Severe, 615 \geq grade 3.

616 (right) Participants with clinically relevant hearing loss (SIOP Boston ototoxicity scale ≥2, n=36)
617 who completed the baseline questionnaire and status on information/advice received on hearing
618 loss (yes/no), hearing evaluated after therapy end (yes/no), self-reported hearing loss (yes/no),
619 hearing difficulties in noisy environments (yes/no) and feeling of bad hearing (yes/no). 95%
620 Confidence intervals are displayed for those reporting "Yes".

^a, Participants with clinically relevant hearing loss who did not complete the baseline
 questionnaire were excluded from this graphic (n=1).


623 Abbreviations: SIOP, International Society of Paediatric Oncology. n, number.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

Supplementary FIGURE SF1 Flowchart illustrating the HEAR-study population, depicting eligible survivors identified by the Swiss Childhood Cancer Registry.

628



629

- 630 Abbreviations: ICCC-3, international classification of childhood cancer, edition 3. n,
- 631 number.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

633 Supplementary TABLE S1 Demographic and clinical characteristics 634 of study population, stratified by response status.

	Total invited N=424	Completed questionnaire	Did not respond to questionnaire	p-value ^a	Cramér's V /
		N=105	N=319		Cohen's d [⊳]
	n (%)	n (%)	n (%)		
Sex				0.08	0.08
Female	199 (47)	57 (54)	142 (45)		
Male	225 (53)	48 (46)	177 (55)		
Age at study, years (Median, IQR)	29 (23-37)	32 (24-37)	29 (22-36)	0.03	0.24
18-25	148 (35)	33 (31)	115 (36)		
26-34	141 (33)	31 (30)	110 (34)		
35-57	135 (32)	41 (39)	94 (29)		
Year of diagnosis (Median,	1999 (1977-	1998 (1977-	2000 (1978-	0.02	0.25
range)	2019)	2018)	2019)		
1977-1995	147 (35)	33 (31)	114 (36)		
1996-2003	153 (36)	39 (37)	114 (36)		
2004-2019	124 (29)	33 (31)	91 (29)		
Time since diagnosis, years (Median, IQR)	22 (1 <mark>6</mark> -30)	23 (19-32)	21 (16-29)	0.03	0.25
3-18	143 (34)	25 (24)	118 (37)		
19-26	144 (34)	40 (38)	104 (33)		
27-44	137 (32)	40 (38)	97 (30)		
Age at cancer diagnosis, years	9 (3.5-13)	8 (4-13)	9 (3-13)	0.87	0.02
(Median, IQR)	0 (0.0 10)	0 (110)	0 (0 10)	0.07	0.02
≤5	147 (35)	33 (31)	114 (36)		
6-12	153 (36)	39 (37)	114 (36)		
13-20	124 (29)	33 (31)	91 (29)		
Diagnostic group of primary	121 (20)	00 (01)	01 (20)	0.01	0.23
neoplasm (ICCC-3)				0.01	0.20
Leukemias (I)	8 (2)	0 (0)	8 (3)		
Lymphomas (II)	17 (4)	7 (7)	10 (3)		
CNS (III)	111 (26)	23 (22)	88 (28)		
Neuroblastoma (IV)	42 (10)	13 (12)	29 (9)		
Retinoblastoma (V)	15 (4)	3 (3)	12 (4)		
Renal tumors (VI)	30 (7)	2 (2)	28 (9)		
Hepatic tumors (VII)	11 (3)	4 (4)	7 (2)		
Malignant bone tumors (VIII)	71 (17)	24 (23)	47 (15)		
Soft tissue (IX)	67 (16)	22 (21)	45 (14)		
Germ cell tumors (X)	49 (12)	7 (7)	42 (13)		
Other (XI)	3 (1)	0 (0)	3 (1)		
Platinum Chemotherapy	U (1)	0 (0)	5(1)	0.50	0.10
No platinum chemotherapy	91 (21)	23 (22)	68 (21)	0.00	0.10
Cisplatin	148 (35)	42 (40)	106 (33)		
Carboplatin	92 (22)	17 (16)	75 (24)		
Cisplatin & Carboplatin	78 (18)	21 (20)	57 (18)		
Unknown	15 (4)	2 (2)	13 (4)		
Cranial radiation		~ (~)		0.57	0.07
No cranial radiation	253 (60)	64 (61)	189 (59)	0.01	0.07
<30 Gray	3 (1)	0 (0)	3 (1)		
≥30 Gray	165 (39)	41 (39)	124 (39)		
Unknown	3 (1)	0 (0)	3 (1)		

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

- 636 Abbreviations: n, number. IQR, Interquartile Range. ICCC-3, international classification
- 637 of childhood cancer, edition 3. CNS, central nervous system.
- 638 ^a, p-values calculated from chi-square statistics for categorical variables and two-sided t-
- 639 test for continuous variables, comparing responders to non-responders.
- 640 ^b, Effect sizes were calculated using Cramér's V for categorical and Cohen's d for
- 641 continuous variables.

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss	
25-Sep-24	

Philippa Jörger

Supplementary TABLE S2 Clinical risk factors for hearing loss in childhood cancer survivors who participated in the HEAR-study (N=105).

	Cranial radiation ≥30 Gray n (%)	No cranial radiation n (%)	Total n (%)
Cisplatin	4 (10)	38 (59)	42 (40)
Carboplatin	7 (17)	10 (16)	17 (16)
Cisplatin & Carboplatin	6 (15)	15 (23)	21 (20)
No platinum chemotherapy	23 (56)	0 (0)	23 (22)
Unknown	1 (2)	1 (2)	2 (2)
Total	41 (100)	64 (100)	105 (100)

Supplementary TABLE S3 Calendar period of last completed hearing test (n=40).

Year	Participants N=40 (n, (%))
<2020	12 (30)
2020-2022	13 (33)
Do not remember	15 (38)

Abbreviations: n, number.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

Supplementary TABLE S4 Characteristics of participants by 654 information status and factors associated with information status; 655 results from univariable logistic regressions. 656

657

	Informed/Advised yes N=46	Informed/Advised no or don't know know N=59	Univariable OR (95%-CI) N=105	p-value
	n (%)	n (%)		
Sex				
Female Male	24 (52) 22 (48)	33 (56) 26 (44)	1.0 1.2 (0.5-2.5)	0.70
Median age at study (IQR; Range)	29 (22-35; 18-43)	34 (25-45; 19-57)	0.9 (0.9-1.0)	<0.01
Median years since diagnosis (IQR; Range) Median age at diagnosis (IQR; Range)	20 (17-26; 4-43) 10 (4-14; 0-19) 2002 (1996-2005;	27 (22-34; 7-44) 7 (3-13; 0-19) 1995 (1987-2000;	0.9 (0.9-1.0) 1.0 (1.0-1.1) 1.1 (1.0-1.2)	<0.01 0.19 <0.01
Year of diagnosis (IQR; Range)	1979-2018)	1977-2014)	1.1 (1.0-1.2)	\0.01
≤1995 >1995	11 (24) 35 (76)	30 (51) 29 (49)	3.3 (1.4-7.7)	<0.01
Language region				0.20
French German	11 (24) 35 (76)	21 (36) 38 (64)	1.0 1.8 (0.7-4.2)	
Participant education		. ,	()	
Primary or secondary education Tertiary education	29 (63) 17 (37)	33 (56) 26 (44)	1.0 0.7 (0.3-1.6)	0.46
Maternal education ^a				
Primary or secondary education Tertiary education	29 (63) 16 (35)	47 (80) 11 (19)	1.0 2.4 (1.0-5.8) NA	0.06 NA
Missing Paternal education ^a	1 (2)	1 (2)	INA	INA
Primary or secondary education	28 (61)	44 (75)	1.0	
Tertiary education	17 (37)	15 (25)	1.8 (0.8-4.1)	0.18
Missing	1 (2)	0 (0)	NA	NA
Migration background ^a	. (=)	0 (0)		101
No	29 (63)	35 (59)	1.0	
Yes	17 (37)	22 (37)	0.9 (0.4-2.1)	0.87
Missing	0 (0)	2 (3)	NA	NA
Late effects other than hearing loss				
No	9 (20)	24 (41)	1.0	
Yes	37 (80)	35 (59)	2.8 (1.2-6.9)	0.02
Self-reported hearing loss	07 (50)	F4 (00)	4.0	
No Yes	27 (59)	54 (92) 5 (8)	1.0 7.6 (2.6.22.6)	<0.01
General information received on follow-up	19 (41)	5 (8)	7.6 (2.6-22.6)	<0.01
care				
No	24 (52)	43 (73)	1.0	
Yes	22 (48)	16 (27)	2.5 (1.1-5.6)	0.03
Regular visit of follow-up care		. ,	、 , ,	
No	20 (43)	38 (64)	1.0	
Yes	26 (57)	21 (36)	2.4 (1.1-5.2)	0.03
Treatment groups				
Cranial radiation ≥30 Gray only	3 (7)	20 (34)	1.0	
Platinum Chemotherapy only	32 (70)	31 (53)	6.9 (1.9-25.5)	<0.01
Both	11 (24)	6 (10)	12.2 (2.5-58.7)	<0.01
Missing	0	2 (3)	NA	NA

^a, People with missing maternal or paternal education, missing migration background 658

659 and missing cisplatin were excluded from the univariable logistic regression.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss Philippa Jörger 25-Sep-24

- 660 Abbreviations: N, number OR, Odds Ratio. CI, Confidence Interval. IQR, Interquartile
- 661 Range.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

662 **Supplementary TABLE S5** Characteristics of participants by status 663 of prior hearing evaluation; results from univariable logistic 664 regressions.

	Hearing evaluated yes N=40	Hearing evaluated no or didn't know N=65	Univariable OR (95%-CI) N=105	p-value
	n (%)	n (%)		
Sex				
Female	22 (55)	35 (54)	1.0	
Male	18 (45)	30 (46)	1.0 (0.4-2.1)	0.91
Median age at study (IQR; Range)	29 (24-35; 18-48)	34 (24-43; 19-57)	1.0 (0.9-1.0)	0.036
Median years since diagnosis (IQR; Range)	21 (17-26; 4-41)	26 (20-34; 4-44)	0.9 (0.9-1.0)	0.013
Median age at diagnosis (IQR; Range)	9 (3-14; 0-19)	8 (4-13; 0-19)	1.0 (1.0-1.1)	0.57
Year of diagnosis (IQR; Range)	2000 (1996-2005; 1981-2018)	1996 (1988-2002; 1977-2017)	1.1 (1.0-1.1)	0.01
≤1995	9 (23)	32 (49)	3.3 (1.4-8.1)	<0.01
>1995	31 (78)	33 (51)	· · · ·	
Language region				
French	11 (28)	21 (32)	1.0	
German	29 (73)	44 (68)	1.3 (0.5-3.0)	0.60
Participant education				
Primary or secondary education	27 (68)	35 (54)	1.0	
Tertiary education	13 (33)	30 (46)	0.6 (0.2-1.3)	0.17
Maternal education ^a				
Primary or secondary education	24 (60)	52 (80)	1.0	
Tertiary education	15 (38)	12 (18)	2.8 (1.1-6.8)	0.03
Missing	1 (3)	1 (2)	NA	NA
Paternal education ^a	05 (00)	47 (70)	4.0	
Primary or secondary education	25 (63)	47 (72)	1.0	0.00
Tertiary education Missing	14 (35)	18 (28)	1.5 (0.6-3.4) NA	0.38 NA
Missing Migration background ^a	1 (3)	0 (0)	INA	INA
No	24 (60)	40 (62)	1.0	
Yes	16 (40)	23 (35)	1.2 (0.5-2.6)	0.72
Missing	0 (0)	2 (3)	NA	NA
Late effects other than hearing loss	0 (0)	2 (0)		101
No	7 (18)	26 (40)	1.0	
Yes	33 (83)	39 (60)	3.1 (1.2-8.2)	0.02
Self-reported hearing loss		()	- (-)	
No	27 (68)	54 (83)	1.0	
Yes	13 (33)	11 (17)	2.4 (0.9-6.0)	0.07
General information received on follow-up			Y/	
care				
No	20 (50)	47 (72)	1.0	
Yes	20 (50)	18 (28)	2.6 (1.1-6.0)	0.02
Information/advice received on hearing loss				
and hearing screening				
No	7 (18)	52 (80)	1.0	
Yes	33 (83)	13 (20)	18.9 (6.8-52.1)	<0.01
Regular visit of follow-up care	40 (45)	40 (00)	4.0	
No	18 (45)	40 (62)	1.0	0.40
Yes	22 (55)	25 (38)	2.0 (0.9-4.3)	0.10
Treatment groups ^a Cranial radiation ≥30 Gray only	4 (40)	10 (20)	1.0	
Platinum Chemotherapy only	4 (10) 28 (70)	19 (29) 35 (54)	1.0 3.8 (1.2-12.5)	0.03
Both	8 (20)	9 (14)	4.2 (1.0-17.8)	0.05

It is made available under a CC-BY 4.0 International license.	
Manuscript – Awareness Hearing loss	Philippa Jörger
25-Sep-24	

Mi	issing	0 (0)	2 (3)	NA	NA
666					·
667	667 ^a , People with missing maternal or paternal education, missing migration background				
668	and missing platin status were excluded from the univariable logistic regression.				

CCO Alther information OD Orbits OL Operfidence Information IOD Information

- 669 Abbreviations: N, number OR, Odds Ratio. CI, Confidence Interval. IQR, Interquartile
- 670 Range.

It is made available under a CC-BY 4.0 International license . Manuscript – Awareness Hearing loss 25-Sep-24

Philippa Jörger

671 Supplementary TABLE S6 Questions on late effects, hearing loss,
672 information provision, awareness of hearing loss, and
673 sociodemographic characteristics in from the HEAR-study (translated
674 into English).

675

Variable	Question in questionnaire	Answer options			
Presence of late effects	Are you suffering from a late effect of your previous cancer or its treatment?	Yes; no			
Self-reported hearing loss	What late effects do you suffer from?	Open			
General information received regarding follow-up care	Have you received written or verbal information from your pediatric oncologists regarding follow-up care?	Yes; no; don't know			
Information status	Have you been informed that hearing impairment or hearing loss is possible after completion of therapy?	Yes; no; don't know			
	Have you been advised to have your hearing checked after completing your therapy?	Yes; no; don't know			
Regular visit of follow-up care	Do you still go to regular check-ups or follow- up care for your cancer?	Yes; no			
Prior hearing evaluation	Has your hearing been checked after you have completed your cancer treatment?	Yes; no; don't know			
Participant education	What is the highest level of education you have completed?	Obligatory; vocational training; high school; technical college; university			
Education mother/father	What is your mother's/father's highest level of education?	Obligatory; vocational training; high school; technical college; university			
Birthplace mother/father	In which country was your mother/father born?	Switzerland; don't know; other			
Feeling of bad hearing	Do you sometimes have the feeling of not hearing well?	Yes, often; yes, sometimes; no			
Hearing difficulties in noisy environments	Do you have problems following conversations in background noise, in a group, in a restaurant or with background music?	Yes; no			